Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oscar Health, Inc. (NYSE: OSCR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Oscar identifies itself in these filings as a healthcare technology company whose Class A common stock trades on the New York Stock Exchange under the symbol OSCR. Through its reports, investors can review how the company structures its health insurance operations, technology initiatives, and capital markets activities.
Oscar’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide overviews of its Individual & Family health plans, health technology solutions under the +Oscar brand, risk factors, and detailed financial statements. These core filings typically include information on revenues, medical costs, selling, general, and administrative expenses, membership metrics, and key non-GAAP measures such as Adjusted EBITDA, along with management’s discussion of business drivers.
The company’s current reports on Form 8-K offer more targeted updates. Recent 8-K filings describe quarterly financial results, reaffirmed guidance, and capital structure actions such as the issuance of 2.25% Convertible Senior Subordinated Notes due 2030, related capped call transactions, and an exchange agreement involving 7.25% Convertible Senior Notes due 2031. Other 8-Ks detail amendments to investment agreements, the planned termination of a revolving credit facility in connection with a notes offering, and changes to executive employment agreements and compensation structures.
Investors can also use this page to access information on convertible debt terms, events of default, subordination provisions, and potential share dilution from note conversion, all of which are described in Oscar’s indentures and related exhibits. Stock Titan’s AI summaries help explain the implications of these filings, highlight key sections of lengthy documents, and surface important items such as changes in guidance, financing transactions, and governance-related disclosures. This makes it easier to understand how Oscar’s regulatory filings relate to its health insurance operations, technology platform, and long-term financial strategy.
Oscar Health (OSCR) filed a notice that an affiliated holder plans to sell Class A common stock under Rule 144. The filing reports an intended sale of 2,123 Class A shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $35,517.79 at the time of the notice. The issuer had 229,010,000 shares outstanding of this class, giving context to the size of the planned sale.
The shares to be sold come from restricted stock units that vested under a registered plan on 12/01/2025, with a total of 5,118 shares acquired on that date as consideration for services rendered. The signer represents that they are not aware of any non-public material adverse information about Oscar Health’s current or future operations, consistent with Rule 144 requirements.
OSCR received a notice that an insider plans to sell Class A common stock under Rule 144. Mario Schlosser intends to sell 22,195 Class A shares on the NYSE through Morgan Stanley Smith Barney LLC, with an aggregate market value of
The shares to be sold were acquired on
T. Rowe Price Investment Management, Inc. filed Amendment No. 1 to a Schedule 13G reporting its beneficial ownership in Oscar Health, Inc. (Class A). The firm reports 8,322,004 shares of common stock, representing 3.7% of the class, with the Date of Event listed as 09/30/2025.
The filing lists sole voting power over 8,297,290 shares and sole dispositive power over 8,322,004 shares, with no shared voting or dispositive power. It is filed as an investment adviser in accordance with Rule 13d‑1(b). The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filer indicates ownership of 5 percent or less of the class.
Oscar Health (OSCR): Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn filed Amendment No. 3 to Schedule 13G reporting 0 shares and 0% beneficial ownership of Oscar Health’s Class A Common Stock.
The filing shows no sole or shared voting or dispositive power for any reporting person. The stated Date of Event is 09/30/2025, and each certifies the securities were not acquired or held to change or influence control.
Oscar Health (OSCR) reported insider activity by its President of Technology & CTO, who also serves as a director. On 11/11/2025 and 11/12/2025, the insider exercised stock options at $6.36 per share and converted Class B into Class A, then sold shares to cover the cost of exercise and tax withholding.
The insider sold 286,182 Class A shares at a weighted average price of $15.27 on 11/11/2025 and 105,300 shares at a weighted average price of $15.05 on 11/12/2025. Following the transactions, the insider directly owned 501,148 Class A shares. The option referenced is fully vested and expires on December 7, 2025. The filing also lists indirect holdings of Class A shares held by related trusts.
OSCR filed a Form 144 notice for a proposed sale of common stock. The filing lists 105,300 shares to be sold with an aggregate market value of $1,585,133.55, through Morgan Stanley Smith Barney LLC, on or about 11/12/2025. The shares trade on the NYSE.
The securities to be sold were acquired on 11/12/2025 via an exercise of options under a registered plan, with payment in cash. Shares outstanding were 229,010,000 as of the figures provided. The filing also reports sales in the past three months by a named seller: 286,182 shares on 11/11/2025 for $4,369,512.63, and 395,000 shares on 09/22/2025 for $7,280,995.50.
Form 144 is a notice of proposed sale under Rule 144 and does not itself effect a sale; it discloses intent and relevant limits and timing.
Oscar Health (OSCR) filed a Form 144 indicating a proposed sale of 286,182 common shares, with an aggregate market value of $4,369,512.63. The filing lists Morgan Stanley Smith Barney LLC as broker, an approximate sale date of 11/11/2025, and the NYSE as the exchange.
The shares were acquired on 11/11/2025 via exercise of options under a registered plan, paid in cash. As a reference figure, the filing notes 229,010,000 shares outstanding. In the past three months, Mario T Schlosser reported a sale of 395,000 shares on 09/22/2025 for $7,280,995.50.
Oscar Health (OSCR) reported a Q3 2025 net loss and higher revenue. Total revenue was $2,985,984 thousand, up from $2,423,482 thousand a year ago, driven by premium growth and investment income. Net loss attributable to the company was $137,450 thousand, or $0.53 per diluted share, compared with a $54,596 thousand loss in Q3 2024.
Cash and cash equivalents were $2,148,865 thousand, and long‑term debt rose to $686,294 thousand, reflecting the issuance of $410,000 thousand 2.25% convertible senior subordinated notes due 2030 and existing 7.25% notes due 2031. The company recorded risk adjustment transfer payable of $1,771,305 thousand as of September 30, 2025, after increasing estimates based on updated market data.
Oscar ended the quarter with approximately 2.1 million effectuated members and closed acquisitions of INSXCloud, IHC Specialty Benefits, and Healthinsurance.org in May 2025. Subsequent events included note conversions and exchanges, and the purchase of capped calls for $34,440 thousand to mitigate conversion-related dilution on the 2030 notes.
Oscar Health (OSCR) entered an Exchange Agreement with Dragoneer, allowing exchanges of up to $250,000,000 principal of 7.25% convertible senior notes due 2031 through December 14, 2025. On November 5, 2025, Dragoneer exchanged $187,500,000 of these notes for 23,273,179 Class A shares, and the company was relieved of future interest payments on the exchanged debt.
The Agreement also provides for up to $17.8 million of additional consideration, payable in shares and/or cash, pursuant to its terms and conditions. As of November 5, 2025, debt covenants in the 2031 notes Investment Agreement were extinguished, and the company’s $410,000,000 2.25% convertible senior subordinated notes due 2030 ceased to be subordinated to the 2031 notes.
Separately, the company furnished a press release announcing financial results for the quarter ended September 30, 2025 as Exhibit 99.1.
Oscar Health (OSCR) reported a Form 4 showing a director received 1,004 deferred stock units on 10/09/2025, calculated using the Class A closing price of $20.54. Following the transaction, the reporting person beneficially owned 3,749 derivative securities. Under the plan, these units are 100% vested on grant and will be settled for cash or shares, at the company’s discretion, within 45 days of termination of service, a change in control, death, or disability. The director elected DSUs in lieu of cash retainer payments.
FAQ
What is the current stock price of Oscar Health (OSCR)?
What is the market cap of Oscar Health (OSCR)?
